Ascend Wellness Holdings (AAWH) Net Income towards Common Stockholders (2020 - 2026)
Ascend Wellness Holdings (AAWH) posted quarterly Net Income towards Common Stockholders of -$29.5 million for Q1 2026, down 53.15% year-over-year from -$62.9 million in Q1 2025, and up 39.44% quarter-over-quarter from -$48.7 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$29.5 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 53.15% year-over-year to -$29.5 million; the TTM figure through Mar 2026 stood at -$128.4 million (down 49.18% YoY), while the FY2025 annual figure was -$118.2 million, down 39.06% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$29.5 million, up from -$48.7 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $841000.0 in Q2 2023, with the low at -$48.7 million in Q4 2025.
- The 5-year median for Net Income towards Common Stockholders is -$19.3 million (2023), against an average of -$21.3 million.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders jumped 103.97% in 2023, then tumbled 2690.25% in 2024.
- Ascend Wellness Holdings' Net Income towards Common Stockholders stood at -$15.0 million in 2022, then decreased by 28.52% to -$19.3 million in 2023, then gained by 13.19% to -$16.8 million in 2024, then sank by 190.05% to -$48.7 million in 2025, then soared by 39.44% to -$29.5 million in 2026.
- Business Quant data shows AAWH's Net Income towards Common Stockholders at -$29.5 million in Q1 2026, -$48.7 million in Q4 2025, and -$25.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Ascend Wellness Holdings | 86.08 Mn | 19.08 Mn | 45.49 Mn | -9.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.81 Mn |
| Mar 31, 2026 | -29.49 Mn |
| Dec 31, 2025 | -48.70 Mn |
| Sep 30, 2025 | -25.83 Mn |
| Jun 30, 2025 | -24.41 Mn |
| Mar 31, 2025 | -19.26 Mn |
| Dec 31, 2024 | -16.79 Mn |
| Sep 30, 2024 | -28.26 Mn |
| Jun 30, 2024 | -21.78 Mn |
| Mar 31, 2024 | -18.16 Mn |
| Dec 31, 2023 | -19.34 Mn |
| Sep 30, 2023 | -11.24 Mn |
| Jun 30, 2023 | 841,000.00 |
| Mar 31, 2023 | -18.47 Mn |
| Dec 31, 2022 | -15.05 Mn |
| Sep 30, 2022 | -16.86 Mn |
| Jun 30, 2022 | -21.17 Mn |
| Mar 31, 2022 | -27.82 Mn |
| Dec 31, 2021 | -16.51 Mn |
| Sep 30, 2021 | -13.03 Mn |